Moderna Therapeutics and the National Institute of Allergy and Infectious Diseases announced (NIAID) today that researchers had injected the first volunteers of the first coronavirus vaccine in the United States to reach the final testing phase 3. This person hit at 6:45 Eastern Time get to Savannah, Geo., Dr. Anthony Fauci, director of the National Institute of Allergy and infectious diseases of the National Institutes of Health (NIH) told reporters during a press conference. Since the obtaining of study participants randomly assigned to one vaccine or a placebo, and neither the researchers nor the volunteers know who receive them, that person will not know until the data is not blind, if he or she has been vaccinated against COVID-19, in all, 30,000 healthy people is how effective registration are immunized in COVID-19 prevented by the vaccine or a check to determine. “The collaboration between the NIH and Modern, with much support from the warp of a management point has been reached where we can find out … what is the status of the vaccine in its ability in the real world to protect them from disease and be safe, “said Dr. Francis Collins, director of the NIH. Moderna is received by a handful of companies to facilitate federal funding through surgery Warp Speed the development of a vaccine 19 COVID-government program. Since this last phase of testing how well the vaccine works that focus on the earlier stages as well as ensure that the vaccine has been focused that researchers say they will try to enroll volunteers who are more likely to stay Virus. This includes people in high-risk occupations such as health care workers and people in the US area where the virus is currently spreading rapidly. The current network of 89 testing centers suits areas of the country where the virus is spreading, Fauci said. “I think we are a good sampling, in which the activity of the virus, transmission, currently in the country,” he said. This is important because in order to let more people who volunteer in areas where the virus is circulating, the more likely that participants who were exposed to the virus. This would help researchers determine whether people who have been vaccinated with the experimental shot to fight the infection had better protection than those who received placebo faster. Even now, Collins said, he has created a website to help people express interest invite to a study conducted at the inscription attracted 150,000 registrants. Not everyone will qualify for the study, but it is an indication of how much interest and willingness to participate, and how quickly the study reach their destination by volunteers. If the virus continues to circulate widely, estimated Fauci might be possible to obtain a first set of results in November. accounts held the timeline for a couple of weeks in July and August is the goal to enroll 30,000 trained volunteers, and the time for the people in the study received the second dose to get the vaccine, which comes 28 days after the first time and to analyze the data. “You can imagine that if we have a real explosion or eruption of infection in these places where we are present active membership, then we were able to get a response as early as November. But I doubt there is one that remains open possibilities, “he said. Modern and NIAID scientists collaborated to develop the vaccine using a relatively new technology, to make mRNA containing the genetic instructions for proteins. The vaccine contains mRNA that causes the spike protein of SARS-CoV-2, the virus-COVID XIX Once people are vaccinated, recognize their immune cells that strange, viral mRNA and initiate immune responses against him assembly. In theory, if you are subsequently exposed to the real virus, their immune system will be ready for this fight. In previous studies, the vaccine triggered antibodies recovery in people who were infected by the disease similar to the virus to a level. Further tests showed that produced in response to the vaccine, the antibodies could neutralize the laboratory versions of SARS-CoV-2. The recent phase 3 study initiated would be the real test of how the vaccine when confronted with the virus. At the moment, this test is considered successful if the vaccine in preventing people 60% effective to be vaccinated with SARS-CoV-infected 2 ever. This is not as powerful as vaccines, as it is effective for measles, 97%, but “together with the public health measures that [it] would be to control this epidemic at national and global level, a great, great step towards “Fauci said. “I want to see more than [60%], but we will take this money.” The researchers followed the volunteers for a year to see if they develop side effects, and scientists continue to follow it is for another year to pursue their immune responses to find out how long the immunity lasts for provided by the vaccine. Stephan Bancel, CEO of Modern, said the company has already started doses of vaccine in anticipation of a positive outcome from the study for the production. “We are ramping up production … and we are on track to provide 500 million doses in fiscal year 2021,” he said. “The team is working hard to produce nearly a billion doses next year, and I think a billion doses will be feasible. It is yet to develop in the bag, but the 500 million I think in the pocket for the next year. “the company has received nearly $1 billion in federal funds by the Central Research and Development advanced Biomedical its vaccine and the complete final phase of testing. Collins said that a group of public health experts are working to deploy in these first few doses, if and when they are safe and effective, is applied. “It will be tens of millions of doses at the time certainly given effectively the vaccine, [but] it all is not enough,” he said. “Decisions have to be made to have the priority.” He said the Center for Disease Control (CDC) Advisory Committee on Immunization Practices and a specially convened panel of experts from the National Academy of Medicine, is a guide to give priority groups the vaccine needs. “We recognize that COVID-19 into sharp relief, which made health disparities that afflict populations in the United States, where hospitalizations, serious illnesses and deaths have fallen disproportionately on the shoulders of African Americans, Latinx and Native Americans, and we know that this disease is a particular threat to the elderly and people with chronic diseases, “said Collins. “Therefore, if we want to demonstrate the safety and efficacy of the vaccine, we would like to ensure in particular that its those groups they are represented in the trial of the vaccine.” The National Academy panel of interim guidelines should provide Labor Day, it would be open for public discussion, then, and would then form the basis of the recommendations of the Advisory Committee have completed the CDC hopes to late September.
Modern COVID-19 vaccine is undergoing final testing, the researcher of the first dose of the study volunteers
